256 related articles for article (PubMed ID: 2829024)
1. Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
Traunecker A; Lüke W; Karjalainen K
Nature; 1988 Jan; 331(6151):84-6. PubMed ID: 2829024
[TBL] [Abstract][Full Text] [Related]
2. HIV infection is blocked in vitro by recombinant soluble CD4.
Fisher RA; Bertonis JM; Meier W; Johnson VA; Costopoulos DS; Liu T; Tizard R; Walker BD; Hirsch MS; Schooley RT
Nature; 1988 Jan; 331(6151):76-8. PubMed ID: 2829022
[TBL] [Abstract][Full Text] [Related]
3. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.
Hussey RE; Richardson NE; Kowalski M; Brown NR; Chang HC; Siliciano RF; Dorfman T; Walker B; Sodroski J; Reinherz EL
Nature; 1988 Jan; 331(6151):78-81. PubMed ID: 2829023
[TBL] [Abstract][Full Text] [Related]
4. A soluble form of CD4 (T4) protein inhibits AIDS virus infection.
Deen KC; McDougal JS; Inacker R; Folena-Wasserman G; Arthos J; Rosenberg J; Maddon PJ; Axel R; Sweet RW
Nature; 1988 Jan; 331(6151):82-4. PubMed ID: 3257544
[TBL] [Abstract][Full Text] [Related]
5. Receptor molecule blocks HIV.
Weiss RA
Nature; 1988 Jan; 331(6151):15. PubMed ID: 2829021
[No Abstract] [Full Text] [Related]
6. Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.
Farrar WL; Harel-Bellan A; Ferris DK
Crit Rev Immunol; 1988; 8(4):315-39. PubMed ID: 2850890
[TBL] [Abstract][Full Text] [Related]
7. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4.
Landau NR; Warton M; Littman DR
Nature; 1988 Jul; 334(6178):159-62. PubMed ID: 3260352
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.
Weinhold KJ; Lyerly HK; Stanley SD; Austin AA; Matthews TJ; Bolognesi DP
J Immunol; 1989 May; 142(9):3091-7. PubMed ID: 2468713
[TBL] [Abstract][Full Text] [Related]
9. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
Traunecker A; Schneider J; Kiefer H; Karjalainen K
Nature; 1989 May; 339(6219):68-70. PubMed ID: 2541344
[TBL] [Abstract][Full Text] [Related]
10. HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens.
Mann DL; Read-Connole E; Arthur LO; Robey WG; Wernet P; Schneider EM; Blattner WA; Popovic M
J Immunol; 1988 Aug; 141(4):1131-6. PubMed ID: 2840463
[TBL] [Abstract][Full Text] [Related]
11. Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding.
Clayton LK; Sieh M; Pious DA; Reinherz EL
Nature; 1989 Jun; 339(6225):548-51. PubMed ID: 2543930
[TBL] [Abstract][Full Text] [Related]
12. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
Wu L; Gerard NP; Wyatt R; Choe H; Parolin C; Ruffing N; Borsetti A; Cardoso AA; Desjardin E; Newman W; Gerard C; Sodroski J
Nature; 1996 Nov; 384(6605):179-83. PubMed ID: 8906795
[TBL] [Abstract][Full Text] [Related]
13. [HIV envelope proteins are bound by human epidermal Langerhans cells by a binding site which differs from the site on the CD4 molecule, and are internalized by receptor endocytosis].
Schmitt D; Dezutter-Dambuyant C; Hanau D; Schmitt DA; Kolbe HV; Kieny MP; Cazenave JP; Thivolet J
C R Acad Sci III; 1989; 308(10):269-75. PubMed ID: 2543485
[TBL] [Abstract][Full Text] [Related]
14. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.
Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS
J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307
[TBL] [Abstract][Full Text] [Related]
15. HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis.
Mann DL; Lasane F; Popovic M; Arthur LO; Robey WG; Blattner WA; Newman MJ
J Immunol; 1987 Apr; 138(8):2640-4. PubMed ID: 3031162
[TBL] [Abstract][Full Text] [Related]
16. A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus.
Berger EA; Fuerst TR; Moss B
Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2357-61. PubMed ID: 2451247
[TBL] [Abstract][Full Text] [Related]
17. Structural features of CD4 required for binding to HIV.
Ibegbu CC; Kennedy MS; Maddon PJ; Deen KC; Hicks D; Sweet RW; McDougal JS
J Immunol; 1989 Apr; 142(7):2250-6. PubMed ID: 2538505
[TBL] [Abstract][Full Text] [Related]
18. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.
Chaudhary VK; Mizukami T; Fuerst TR; FitzGerald DJ; Moss B; Pastan I; Berger EA
Nature; 1988 Sep; 335(6188):369-72. PubMed ID: 2843774
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
